Paradoxical suppression of poly-specific broadly neutralizing antibodies in the presence of strain-specific neutralizing antibodies following HIV infection

Journal of Theoretical Biology

Volumn 277, Issue 1, 2011, Pages 55-66

  Ciupe, Stanca M ^a   De Leenheer, Patrick ^b   Kepler, Thomas B ^c  

^a UNIVERSITY OF LOUISIANA AT LAFAYETTE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Antibody response modeling; HIV infection; Viral dynamics

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; NEUTRALIZING ANTIBODY;

ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNIZATION; NUMERICAL MODEL;

ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; B LYMPHOCYTE ACTIVATION; CONTROLLED STUDY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; MATHEMATICAL MODEL; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; VIRAL CLEARANCE; VIRUS CELL INTERACTION; VIRUS STRAIN;

ANTIBODIES, NEUTRALIZING; ANTIBODY FORMATION; ANTIBODY SPECIFICITY; HIV; HIV ANTIBODIES; HIV INFECTIONS; IMMUNIZATION; MODELS, IMMUNOLOGICAL; SPECIES SPECIFICITY;

EID: 79952458645     PISSN: 00225193     EISSN: 10958541     Source Type: Journal    
DOI: 10.1016/j.jtbi.2011.01.050     Document Type: Article

References (45)

1. Aasa-Chapman M., Hayman A., Newton P., et al. Development of the antibody response in acute HIV-1 infection. AIDS 2004, 18:371-381.
2. Antia R., Pilyugin S., Ahmed R. Models of immune memory: on the role of cross-reactive stimulation, competition, and homeostasis in maintaining immune memory. Proc. Natl. Acad. Sci. USA 1998, 95:14926-14931.
3. Arnott A., Jardine D., Wilson K., Gorry P., Merlin K., Grey P., Law M., Dax E., Kelleher A., Smith D., McPhee D. High viral fitness during acute HIV-1 infection. PLoS One 2010, 5(9):e12631.
4. Bachmann M., Hengartner H., Zinkernagel R. Immunization with recombinant protein: conditions for cytotoxic T cells and/or antibody induction. Med. Microbiol. Immunol. 1994, 183(6):315-324.
5. Blankson J., Persaud D., Siliciano R. The challenge of viral reservoirs in HIV-1 infection. Annu. Rev. Med. 2002, 53:557-593.
6. Boer R.D., Freitas A., Perelson A. Resource competition determines selection of B cell repertoires. J. Theor. Biol. 2001, 212:333-343.
7. Borghans J., Taams L., Wauben M., Boer R.D. Competition for antigenic sites during T cell proliferation: a mathematical interpretation of in vitro data. Proc. Natl. Acad. Sci. USA 1999, 96:10782-10787.
8. Buchacher A., Predl R., Strutzenberger K., Steinfellner W., Trkola A., Purtscher M., Gruber G., Tauer C., Steindl F., Jungbauer A., et al. Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization. AIDS Res. Hum. Retroviruses 1994, 10:359-369.
9. Burton D., Desrosiers R., Doms R., et al. HIV vaccine design and the neutralizing antibody problem. Nat. Immunol. 2004, 5:233-236.
10. Burton D., Stanfield R., Wilson I. Antibody vs. HIV in a clash of evolutionary titans. Proc. Natl. Acad. Sci. USA 2005, 102:14943-14948.
11. Ciupe S., de Bivort B., Bortz D., Nelson P. Estimates of kinetic parameters from HIV patient data during primary infection through the eyes of three different models. Math. Biosci. 2006, 200:1-27.
12. Deem M., Lee H. Sequence space localization in the immune system response to vaccination and disease. Phys. Rev. Lett. 2003, 91:068101.
13. Dhillon A., Donners H., Pantophlet R., Johnson W., Decker J., Shaw G., Lee F., Richman D., Doms R., Vanham G., Burton D. Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors. J. Virol. 2007, 81:6548-6562.
14. Douek D., Kwong P., Nabel G. The rational design of an AIDS vaccine. Cell 2006, 124:677.
15. Fauci A., et al. HIV vaccine research: the way forward. Science 2008, 321:530-532.
16. Gilbert P., Peterson M., Follmann D., Hudgens M., Francis D., Gurwith M., Heyward W., Jobes D., Popovic V., Self S., Sinangil F., Burke D., Berman P. Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. J. Infect. Dis. 2005, 191:647-649.
17. Haynes B., Fleming J., Clair E.S., Katinger H., Stiegler G., Kunert R., Robinson J., Scearce R., Plonk K., Staats H., Ortel T., Liao H., Alam S. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 2005, 308:1906-1908.
18. Haynes B., Montefiori D. Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates. Expert Rev. Vaccines 2006, 5:347-363.
19. Heyman B. Feedback regulation by igg antibodies. Immunol. Lett. 2003, 88:157-161.
20. Ho D., Neumann A., Perelson A., Chen W., Leonard J., Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995, 373:123-126.
21. Hodgkin P., Lee J., Lyons A. B cell differentiation and isotype switching is related to division cycle number. J. Exp. Med. 1996, 184(1):277-281.
22. Hollinger F., Liang T. Hepatitis B Virus 2001, Lippincott Williams & Wilkins, Philadelphia, pp. 2971-3036. fourth ed.
23. Hone D.M., DeVico A.L., Fouts T.R., Onyabe D.Y., Agwale S.M., Wambebe C.O., Blattner W.A., Gallo R.C., Lewis G.K. Development of vaccination strategies that elicit broadly neutralizing antibodies against human immunodeficiency virus type 1 in both the mucosal and systemic immune compartments. J. Hum. Virol. 2002, 5:11-23.
24. Janeway, C., Travers, P., Walport, M., Shlomchik, M., 2001. Immunobiology. vol. 5. Garland Publishing, New York, NY.
25. Leenheer P.D., Pilyugin S. Immune response to a malaria infection: properties of a mathematical model. J. Biol. Dyn. 2008, 2:102-120.
26. Levesque M., Moody M., et al. Polyclonal B cell differentiation and loss of gastrointestinal tract germinal centers in the earliest stages of HIV-1 infection. PLoS Med. 2009, 6(7):1-19.
27. Li Y., Migueles S., Welcher B., Svehla K., Phogat A., Louder M., et al. Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nat. Med. 2007, 13:1032-1034.
28. Moore P., Crooks E., Porter L., Zhu P., Cayanan C., Grise H., Corcoran P., Zwick M., Franti M., Morris L., Roux K., Burton D., Binley J. Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1. J. Virol. 2006, 80:2515-2528.
29. Nowak M., May R. Virus Dynamics 2000, Oxford University Press, Oxford.
30. Oprea M., Perelson A. Exploring the mechanisms of primary antibody responses to T cell-dependent antigens. J. Theor. Biol. 1996, 181:215-236.
31. Pantophlet R., Burton D. Gp120: target for neutralizing HIV-1 antibodies. Annu. Rev. Immunol. 2006, 24:739-769.
32. Parren P., Moore J., Burton D., Sattentau Q. The neutralizing antibody response to HIV-1: viral evasion and escape from humoral immunity. AIDS 1999, 13(Suppl. A). (S137-62).
33. Perelson A., et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 1997, 387:188-191.
34. Perelson A., Nuemann A., Markowitz M., Leonard J., Ho D. HIV-1 dynamics in vivo: virion clearance rate, infected cell lifespan, and viral generation time. Science 1996, 271:1582-1586.
35. Priddy F., Brown D., Kublin J., Monahan K., Wright D., Lalezari J., Santiago S., Marmor M., Lally M., Novak R., Brown S., Kulkarni P., Dubey S., Kierstead L., Casimiro D., Mogg R., DiNubile M., Shiver J., Leavitt R., Robertson M., Mehrotra D., Quirk E., Group M.V.-S. Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade b gag/pol/nef vaccine in healthy adults. Clin. Infect. Dis. 2008, 46(11):1769-1781.
36. Rerks-Ngarm S., Pitisuttithum P., Nitayaphan S., Kaewkungwal J., Chiu J., Paris R., Premsri N., Namwat C., de Souza M., Adams E., Benenson M., Gurunathan S., Tartaglia J., McNeil J., Francis D., Stablein D., Birx D., Chunsuttiwat S., Khamboonruang C., Thongcharoen P., Robb N., Michael N., Kunasol P., Kim J., Investigators M.-T. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 2009, 361:2209-2220.
37. Richman D., Wrin T., Little S., Petropoulos C. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc. Natl. Acad. Sci. USA 2003, 100:4144-4149.
38. Stafford M., Corey L., Cao Y., Daar E., Ho D., Perelson A. Modeling plasma virus concentration during primary infection. J. Theor. Biol. 2000, 203:285.
39. Stebbing J., Gazzard B., Douek D. Where does HIV live?. N. Engl. J. Med. 2004, 350:1872-1880.
40. Tomaras G., Yates N., Liu P., Qin L., Fouda G., Chavez L., Decamp A., Parks R., et al. Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin IgM and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. J. Virol. 2008, 82:12449-12463.
41. Walker B., Korber B. Immune control of HIV: the obstacles of HLA and viral diversity. Nat. Immunol. 2001, 2:473-475.
42. Wei X., Decker J., Wang S., Hui H., Kappes J., Wu X., et al. Antibody neutralization and escape by HIV-1. Nature 2003, 422:307-312.
43. Wyatt R., Sodroski J. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 1998, 280:1884-1888.
44. Zhang L., Ribeiro R., Mascola J., Lewis M., Stiegler G., Katinger H., Perelson A., Davenport M. Effects of antibody on viral kinetics in SHIV infection: Implications for vaccination. J. Virol. 2004, 78:5520-5522.
45. Zhou T., Georgiev I., Wu X., Yang Z.-Y., Dai K., Finzi A., Do Kwon Y., Scheid J.F., Shi W., Xu L., Yang Y., Zhu J., Nussenzweig M.C., Sodroski J., Shapiro L., Nabel G.J., Mascola J.R., Kwong P.D. Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01. Science 2010, 329(5993):811-817.